273 related articles for article (PubMed ID: 31039062)
1. Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study.
Schleyer T; Hui S; Wang J; Zhang Z; Knapp K; Baker J; Chase M; Boggs R; Simpson RJ
J Manag Care Spec Pharm; 2019 May; 25(5):544-554. PubMed ID: 31039062
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
[TBL] [Abstract][Full Text] [Related]
3. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
[TBL] [Abstract][Full Text] [Related]
4. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.
Toth PP; Danese M; Villa G; Qian Y; Beaubrun A; Lira A; Jansen JP
J Med Econ; 2017 Jun; 20(6):555-564. PubMed ID: 28097904
[TBL] [Abstract][Full Text] [Related]
5. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
6. Cost Effectiveness of Achieving Targets of Low-Density Lipoprotein Particle Number Versus Low-Density Lipoprotein Cholesterol Level.
Grabner M; Winegar DA; Punekar RS; Quimbo RA; Cziraky MJ; Cromwell WC
Am J Cardiol; 2017 Feb; 119(3):404-409. PubMed ID: 27887691
[TBL] [Abstract][Full Text] [Related]
7. Effect of the Million Hearts Cardiovascular Disease Risk Reduction Model on Initiating and Intensifying Medications: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Peterson GG; Pu J; Magid DJ; Barterian L; Kranker K; Barna M; Conwell L; Rose A; Blue L; Markovitz A; McCall N; Markovich P
JAMA Cardiol; 2021 Sep; 6(9):1050-1059. PubMed ID: 34076665
[TBL] [Abstract][Full Text] [Related]
8. Assessing the association between medication adherence, as defined in quality measures, and disease-state control, health care utilization, and costs in a retrospective database analysis of Medicare supplemental beneficiaries using statin medications.
Axon DR; Vaffis S; Chinthammit C; Lott BE; Taylor AM; Pickering M; Black H; Warholak T; Campbell PJ
J Manag Care Spec Pharm; 2020 Dec; 26(12):1529-1537. PubMed ID: 33251989
[No Abstract] [Full Text] [Related]
9. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
10. Intensive statin therapy for Indians: Part-I. Benefits.
Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Schlackow I; Kent S; Herrington W; Emberson J; Haynes R; Reith C; Collins R; Landray MJ; Gray A; Baigent C; Mihaylova B;
Kidney Int; 2019 Jul; 96(1):170-179. PubMed ID: 31005271
[TBL] [Abstract][Full Text] [Related]
12. Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
Marrett E; Zhao C; Zhang NJ; Zhang Q; Ramey DR; Tomassini JE; Tershakovec AM; Neff DR
Vasc Health Risk Manag; 2014; 10():237-46. PubMed ID: 24851051
[TBL] [Abstract][Full Text] [Related]
13. Primary Prevention Using Cholesterol-Lowering Medications in Patients Meeting New Treatment Guidelines: A Retrospective Cohort Analysis.
Han X; Fox DS; Chu M; Dougherty JS; McCombs J
J Manag Care Spec Pharm; 2018 Nov; 24(11):1078-1085. PubMed ID: 30362921
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden.
Martikainen JA; Soini E; Paulsson T
Curr Med Res Opin; 2010 Feb; 26(2):389-96. PubMed ID: 20001451
[TBL] [Abstract][Full Text] [Related]
15. Statins for the primary prevention of cardiovascular disease.
Taylor F; Huffman MD; Macedo AF; Moore TH; Burke M; Davey Smith G; Ward K; Ebrahim S
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004816. PubMed ID: 23440795
[TBL] [Abstract][Full Text] [Related]
16. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
17. Association Between Achieved Low-Density Lipoprotein Levels and Major Adverse Cardiac Events in Patients With Stable Ischemic Heart Disease Taking Statin Treatment.
Leibowitz M; Karpati T; Cohen-Stavi CJ; Feldman BS; Hoshen M; Bitterman H; Suissa S; Balicer RD
JAMA Intern Med; 2016 Aug; 176(8):1105-13. PubMed ID: 27322095
[TBL] [Abstract][Full Text] [Related]
18. Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
Soran H; Adam S; Durrington PN
Atherosclerosis; 2018 Nov; 278():135-142. PubMed ID: 30273874
[TBL] [Abstract][Full Text] [Related]
19. Associations between statin adherence level, health care costs, and utilization.
Zhao Y; Zabriski S; Bertram C
J Manag Care Spec Pharm; 2014 Jul; 20(7):703-13. PubMed ID: 24967523
[TBL] [Abstract][Full Text] [Related]
20. A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention.
Thanassoulis G; Sniderman AD; Pencina MJ
JAMA Cardiol; 2018 Nov; 3(11):1090-1095. PubMed ID: 30422172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
